scott tagawa, md, elaborates on what may account for resistance to psma radioligand therapies
Published 4 years ago • 23 plays • Length 1:56
Download video MP4
Download video MP3
Similar videos
-
1:21
scott tagawa, md, on promising psma products in development for prostate cancer treatment
-
7:17
scott tagawa, md, on psma targeting in prostate cancer treatment
-
9:23
scott tagawa, m.d. on psma pet-ct and its utility in prostate cancer - part 1
-
4:13
scott tagawa, md, on the prostate cancer treatment pipeline
-
2:08
scott tagawa md, considers next steps in the development of the psma-targeted alpha emitter in mcrpc
-
5:28
psma imaging: vision trial with dr. scott tagawa
-
3:32
scott tagawa, md, explains how psma pet imaging is utilized with psma-based therapies
-
1:51
dr. tagawa on remaining questions with psma-targeted radionuclide therapy in mcrpc
-
7:52
does high psa levels = prostate cancer? | dr steven tucker
-
2:16
how does a prostate-specific antigen (psa) test work?
-
6:21
what is adjuvant hormone therapy for prostate cancer | ask a prostate expert, mark scholz, md
-
2:03
scott tagawa, md, defines the 177lutethium beta emitter and the 225actinium alpha emitter
-
8:52
scott tagawa, m.d. on psma pet-ct and its utility in prostate cancer - part 2
-
26:28
radiogland therapy optimization of prostate specific membrane antigentargeted radiation
-
3:25
scott tagawa, md, discusses the results of phase i dose-escalation study regarding mcrpc
-
5:49
scott tagawa, md, on the impact of racial disparity and covid-19 on prostate cancer clinical trials
-
1:11
scott tagawa, md, shares results of phase 1 dose escalation study of 225ac-j591 in mpc patients
-
2:29
dr. tagawa on brca2 in patients with prostate cancer receiving psma-targeted radionuclide therapy
-
2:01
scott tagawa, m.d., m.s.
-
1:31
dr. tagawa discusses agents targeted against psma
-
7:14
psma-targeted alpha emitter 225ac-j591 for mcrpc
-
1:32
metastatic prostate cancer treatment: a paradigm shift
Clip.africa.com - Privacy-policy